Editas Medicine Inc (EDIT) - Net Assets
Based on the latest financial reports, Editas Medicine Inc (EDIT) has net assets worth $105.28 Million USD as of June 2026. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($237.36 Million) and total liabilities ($132.08 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check EDIT PP&E to net assets ratio to assess the company's strategic physical and investment asset allocation.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $105.28 Million |
| % of Total Assets | 44.35% |
| Annual Growth Rate | N/A |
| 5-Year Change | -95.07% |
| 10-Year Change | -79.73% |
| Growth Volatility | 45.69 |
Editas Medicine Inc - Net Assets Trend (2013–2025)
This chart illustrates how Editas Medicine Inc's net assets have evolved over time, based on quarterly financial data. For live market cap and overall valuation, see how much is Editas Medicine Inc worth.
Annual Net Assets for Editas Medicine Inc (2013–2025)
The table below shows the annual net assets of Editas Medicine Inc from 2013 to 2025. Also explore Editas Medicine Inc net asset momentum to track the company's year-over-year net asset growth rate.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | $27.29 Million | -79.68% |
| 2024-12-31 | $134.27 Million | -61.54% |
| 2023-12-31 | $349.10 Million | -3.21% |
| 2022-12-31 | $360.68 Million | -34.85% |
| 2021-12-31 | $553.64 Million | +40.67% |
| 2020-12-31 | $393.59 Million | +49.97% |
| 2019-12-31 | $262.44 Million | +11.13% |
| 2018-12-31 | $236.16 Million | +13.50% |
| 2017-12-31 | $208.08 Million | +54.58% |
| 2016-12-31 | $134.61 Million | +261.95% |
| 2015-12-31 | $-83.11 Million | -443.51% |
| 2014-12-31 | $-15.29 Million | -767.39% |
| 2013-12-31 | $-1.76 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Editas Medicine Inc's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 162674000000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2025)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $10.00K | 0.04% |
| Other Components | $1.66 Billion | 6067.80% |
| Total Equity | $27.29 Million | 100.00% |
Editas Medicine Inc Competitors by Market Cap
The table below lists competitors of Editas Medicine Inc ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Fulgent Sun International Holding Co Ltd
TW:9802
|
$404.00 Million |
|
Renxin New Material Co. Ltd. A
SHE:301395
|
$404.05 Million |
|
TARC Limited
NSE:TARC
|
$404.06 Million |
|
Suzhou Weizhixiang Food Co. Ltd.
SHG:605089
|
$404.08 Million |
|
Fujian SBS Zipper Science Tech
SHE:002098
|
$403.90 Million |
|
Smcp SAS
PA:SMCP
|
$403.85 Million |
|
Bel Fuse A Inc
NASDAQ:BELFA
|
$403.85 Million |
|
Kolte - Patil Developers Limited
NSE:KOLTEPATIL
|
$403.56 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Editas Medicine Inc's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 134,274,000 to 27,288,000, a change of -106,986,000 (-79.7%).
- Net loss of 160,060,000 reduced equity.
- New share issuances of 42,848,000 increased equity.
- Other comprehensive income decreased equity by 268,000.
- Other factors increased equity by 10,494,000.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-160.06 Million | -586.56% |
| Share Issuances | $42.85 Million | +157.02% |
| Other Comprehensive Income | $-268.00K | -0.98% |
| Other Changes | $10.49 Million | +38.46% |
| Total Change | $- | -79.68% |
Book Value vs Market Value Analysis
This analysis compares Editas Medicine Inc's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 8.55x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2013-12-31 | $-0.06 | $2.63 | x |
| 2014-12-31 | $-5.97 | $2.63 | x |
| 2015-12-31 | $-2.33 | $2.63 | x |
| 2016-12-31 | $4.18 | $2.63 | x |
| 2017-12-31 | $5.16 | $2.63 | x |
| 2018-12-31 | $5.01 | $2.63 | x |
| 2019-12-31 | $5.25 | $2.63 | x |
| 2020-12-31 | $6.72 | $2.63 | x |
| 2021-12-31 | $8.19 | $2.63 | x |
| 2022-12-31 | $5.25 | $2.63 | x |
| 2023-12-31 | $4.60 | $2.63 | x |
| 2024-12-31 | $1.63 | $2.63 | x |
| 2025-12-31 | $0.31 | $2.63 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Editas Medicine Inc utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -586.56%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -395.01%
- • Asset Turnover: 0.22x
- • Equity Multiplier: 6.84x
- Recent ROE (-586.56%) is below the historical average (-88.65%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2013 | 0.00% | 0.00% | 0.00x | 0.00x | $-5.17 Million |
| 2014 | 0.00% | 0.00% | 0.00x | 0.00x | $-12.16 Million |
| 2015 | 0.00% | -4475.14% | 0.01x | 0.00x | $-64.59 Million |
| 2016 | -72.20% | -1605.53% | 0.03x | 1.70x | $-110.64 Million |
| 2017 | -57.83% | -876.49% | 0.04x | 1.79x | $-141.13 Million |
| 2018 | -46.56% | -344.28% | 0.08x | 1.78x | $-133.57 Million |
| 2019 | -50.96% | -651.43% | 0.04x | 1.94x | $-159.99 Million |
| 2020 | -27.80% | -120.59% | 0.16x | 1.45x | $-148.77 Million |
| 2021 | -33.43% | -724.66% | 0.04x | 1.22x | $-240.47 Million |
| 2022 | -56.66% | -1036.69% | 0.04x | 1.43x | $-240.42 Million |
| 2023 | -43.89% | -196.13% | 0.16x | 1.43x | $-188.13 Million |
| 2024 | -176.57% | -733.72% | 0.09x | 2.54x | $-250.52 Million |
| 2025 | -586.56% | -395.01% | 0.22x | 6.84x | $-162.79 Million |
Industry Comparison
This section compares Editas Medicine Inc's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $161,895,707
- Average return on equity (ROE) among peers: -42.53%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Editas Medicine Inc (EDIT) | $105.28 Million | 0.00% | 1.25x | $403.92 Million |
| Aardvark Therapeutics, Inc. Common Stock (AARD) | $-34.80 Million | 0.00% | 0.00x | $109.30 Million |
| Abcellera Biologics Inc (ABCL) | $1.06 Billion | -15.42% | 0.29x | $2.99 Billion |
| Abeona Therapeutics Inc (ABEO) | $170.10 Million | -16.06% | 0.05x | $310.51 Million |
| Acumen Pharmaceuticals Inc (ABOS) | $-11.42 Million | 0.00% | 0.00x | $155.29 Million |
| Abpro Holdings, Inc. (ABP) | $-12.35 Million | 0.00% | 0.00x | $2.00 Million |
| Absci Corp (ABSI) | $176.18 Million | -62.76% | 0.23x | $1.35 Billion |
| Arbutus Biopharma Corp (ABUS) | $38.29 Million | -30.60% | 0.11x | $906.70 Million |
| ABVC Biopharma Inc (ABVC) | $2.46 Million | -172.46% | 1.68x | $28.25 Million |
| Abivax SA American Depositary Shares (ABVX) | $34.66 Million | -45.66% | 0.56x | $9.31 Billion |
| ACADIA Pharmaceuticals Inc (ACAD) | $199.76 Million | -82.32% | 0.11x | $4.61 Billion |
About Editas Medicine Inc
Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. The company develops a proprietary gene editing platform based on CRISPR technology. Its lead program is EDIT-401, a one-time therapy designed to reduce LDL cholesterol through the upregulation of the LDL receptor to treat hyperlipidemia. The… Read more